|
||||||||||||||||||
|
|
||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq. DescriptionThe RIK-2 monoclonal antibody reacts with human TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily. TRAIL is expressed by normal human T, B and NK cells and by several human tumor lines. Interaction of TRAIL with its ligand, Apo-2, induces apoptosis. RIK-2 blocks TRAIL-induced apoptosis. Applications ReportedFor research use only, not for diagnostic or therapeutic use. The RIK-2 antibody has been reported for use in flow cytometric analysis. Applications TestedThe RIK-2 antibody has been pre-titrated and tested by flow cytometric analysis of human TRAIL transfected cells. This can be used at 20 μl per million cells in a 100 μl total staining volume. References
Kayagaki, N., N. Yamaguchi, et al. (1999). "Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells." J Immunol 163(4): 1906-13. Kaplan, M. J., D. Ray, et al. (2000). "TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages [In Process Citation]." J Immunol 164(6): 2897-904. Kayagaki, N., N. Yamaguchi, et al. (1999). "Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity." J Immunol 162(5): 2639-47. Related ProductsCat. 12-4714 Phycoerythrin (PE) Mouse IgG1, K Isotype Control |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
|
Copyright © 2000-2008 eBioscience, Inc. Product For Research Use Only: Not for further distribution without written consent. |